MOLIROM SRL

Their core work

MOLIROM SRL is a small Italian biotech company based in Rome that specializes in membrane protein biochemistry and structure-based drug discovery. Their core work involves producing and stabilizing membrane proteins — notoriously difficult targets in pharmaceutical research — and applying structural biology techniques, including synchrotron and XFEL-based methods, to characterize how these proteins behave at the molecular level. They operate at the intersection of protein science and pharmaceutical drug design, contributing specialist biochemical and biophysical expertise to international research consortia. Their work is directly relevant to pharmaceutical companies and academic groups developing therapies that target membrane-bound proteins such as receptors, transporters, and ion channels.

What they specialise in

How they've shifted over time

In their first H2020 project (X-probe, 2015-2018), MOLIROM's involvement was centered on advanced physical methods — XFEL and synchrotron radiation as tools for probing protein structure and dynamics, a highly technical, instrumentation-heavy area with limited direct commercial application. By their second project (ProMeTeus, 2019-2023), the focus had shifted toward biological and pharmaceutical application: high-throughput membrane protein production, stabilization protocols, and the direct use of structural data in drug design workflows. The direction is clear — from structural methodology toward pharmaceutical-facing application of that methodology, suggesting a deliberate positioning closer to the drug discovery pipeline.

MOLIROM is moving from fundamental structural biology instrumentation toward the membrane protein production and stabilization bottlenecks that directly block pharmaceutical drug target characterization — a trajectory pointing toward applied biotech and drug discovery services.

How they like to work

MOLIROM has participated exclusively as a non-coordinating partner in both H2020 projects, consistent with a specialist contributor that joins consortia for a defined technical niche rather than to lead project management or administrative coordination. Their involvement in MSCA-RISE (staff exchange) and MSCA-ITN-ETN (doctoral training network) schemes indicates comfort with hosting visiting researchers and operating within collaborative, mobility-focused scientific environments. Despite only two projects, they engaged with 18 unique partners across 7 countries, suggesting active integration within each consortium rather than peripheral or token participation.

MOLIROM has built connections with 18 unique partner organizations across 7 countries through just two projects, a notably broad footprint for their size, reflecting the multi-institutional nature of MSCA training and exchange programs. Their network is predominantly European academic and research institutions, which is typical for MSCA scheme participation.

What sets them apart

As a private SME rather than a university or public research institute participating in MSCA schemes focused on membrane protein science, MOLIROM occupies an unusual niche — bringing industry-side biochemical capabilities into academic-led research consortia. This makes them a credible bridge partner for pharmaceutical companies seeking access to academic structural biology networks, or for academic consortia requiring an industrial partner with hands-on membrane protein handling and production know-how. Their Rome base also provides potential access to Italian pharmaceutical and biotech industry connections.

Highlights from their portfolio

• X-probe
  The largest funded project for this organization (EUR 258,061), involving advanced XFEL and synchrotron radiation techniques — specialized infrastructure typically accessible only to major national or international research facilities.
• ProMeTeus
  Directly addresses the bottleneck of membrane protein production and stabilization for drug design, one of the most commercially significant unsolved challenges in modern pharmaceutical research.